alexa
Reach Us +1-218-451-2974
Eric M Reiman | OMICS International
ISSN: 2161-0460

Journal of Alzheimers Disease & Parkinsonism
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences

12th World Congress on Alzheimers Disease & Dementia

Budapest, Hungary
Share This Page

Eric M Reiman

University of Arizona

Biography

Dr. Reiman is executive director of the Banner Alzheimer's Institute, chief executive officer of Banner Research, clinical director of Neurogenomics at the Translational Genomics Research Institute, professor of Psychiatry at the University of Arizona, university professor of Neuroscience at Arizona State University, and director of the Arizona Alzheimer's Consortium.

Dr. Reiman's research interests include brain imaging, genomics, the unusually early detection and tracking of Alzheimer's disease (AD), and the accelerated evaluation of AD prevention therapies. He is also interested in strategies to establish a new standard of dementia care for patients and family caregivers in the emerging health care financing system and the development of new models of collaboration in biomedical research. He is an author of more than 250 publications and a principal investigator of several NIH grants.

Dr. Reiman and his BAI colleagues, Pierre Tariot and Jessica Langbaum, lead the Alzheimer's Prevention Initiative (API), which has helped to launch a new era in Alzheimer's prevention research. He is a recipient of the Potamkin Prize for his pioneering contributions to the field.

Research Interest

Alzheimer’s disease; Parkinson’s disease; Therapy development; Precompetitive consortium

Publications
Top